Global Trade Alert
Global Trade Alert

Back to state act

United States of America: Agreement with Pfizer on most-favored-nation drug pricing and tariff exemption

Description

On 30 September 2025, the U.S. Administration announced an agreement with Pfizer Inc, granting the company a three-year grace period from Section 232 pharmaceutical tariffs. In exchange for this exemp...

Sign in or create a free account to see full description

Intervention Details

Intervention Type

Import tariff

MAST Chapter

Tariff measures

Implementation date

No implementation date

Revocation date

No revocation date

Implementation level

National

Affected flow

Inward

Announced as temporary

No

Eligible firms

firm-specific

Affected Trading Partners

Graph

Table

Affected Sectors

Sign in to access 2 sectors

Affected Products

Sign in to access 11 products

Threads

See all

Harmful Trade Policy Measures

This Thread tracks harmful trade policy interventions affecting all products. Covering all types of interventions monitored by Global Trade Alert, it highlights how the yearly number of these measures has evolved over time.

Published: 04 Sep 2024

70619

interventions

194

jurisdictions

United States: Drug Pricing Agreements

This Thread tracks the U.S. Administration’s agreements with pharmaceutical companies. It is based on the Executive Order titled “Delivering Most-Favored-Nation (MFN) Prescription Drug Pricing to American Patients.” These agreements include tariff relief measures for pharmaceutical companies in return for their commitments to implement most-favored-nation pricing for their drugs and to invest i...

Published: 11 Nov 2025

68

interventions

2

jurisdictions